The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

27 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold.EBI
The University of Kansas
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.EBI
Shandong University
Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.EBI
Sloan-Kettering Institute For Cancer Research
Development of radamide analogs as Grp94 inhibitors.EBI
The University of Kansas
Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.EBI
Vertex Pharmaceuticals
Correlation between chemotype-dependent binding conformations of HSP90a/ß and isoform selectivity-Implications for the structure-based design of HSP90a/ß selective inhibitors for treating neurodegenerative diseases.EBI
Vertex Pharmaceuticals
Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.EBI
Memorial Sloan-Kettering Cancer Center
EC144 is a potent inhibitor of the heat shock protein 90.EBI
Biogen Idec
Heat shock protein 90: inhibitors in clinical trials.EBI
Biogen Idec
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.EBI
Infinity Pharmaceuticals
Synthesis and Validation of the First Cell-Impermeable Hsp90α-Selective Inhibitors.EBI
The University of Notre Dame
Structure-Activity Relationship Study of Tertiary Alcohol Hsp90α-Selective Inhibitors with Novel Binding Mode.EBI
The University of Notre Dame
Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.EBI
National Institute of Diabetes & Digestive & Kidney Diseases
Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.EBI
Shandong University
Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects.EBI
China Pharmaceutical University
Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.EBI
Taiho Pharmaceutical
Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity.EBI
Ewha Womans University
The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with EBI
The University of Notre Dame
Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.EBI
China Pharmaceutical University
Biological Evaluation of 5'-(EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.EBI
Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif)
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.EBI
China Pharmaceutical University
Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis.EBI
China Pharmaceutical University
Resorcinol-Based Grp94-Selective Inhibitors.EBI
The University of Kansas
Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.EBI
Hauptman-Woodward Medical Research Institute
Therapeutic compoundsBDB
Celgene Quanticel Research